Senators introduce regenerative medicine bill

Senators Barbara Boxer (D-CA) and Mark Kirk (R-IL) introduce legislation that will establish a national strategy to support regenerative medicine (RM) research.

Among the requirements of the Regenerative Medicine Promotion Act are: a report by the GAO identifying all ongoing federal programs and activities pertaining to RM, the establishment of a Regenerative Medicine Coordinating Council and the maintenance of a national strategy for the promotion of RM R&D.

Companies involved in the space include ONVO, HART, CUR, CYTX, STEM, ATHX.

From other sites
Comments (26)
  • lbashaw
    , contributor
    Comments (27) | Send Message
    TNGN has proprietary regenerative tech
    14 Mar 2014, 02:11 PM Reply Like
  • skippy the kangaroo..
    , contributor
    Comments (74) | Send Message
    TNGN r u for real?
    16 Mar 2014, 12:04 PM Reply Like
  • mgaines0225
    , contributor
    Comment (1) | Send Message
    I agree that TNGN should be on this list.
    16 Mar 2014, 09:30 PM Reply Like
  • wafflemaker
    , contributor
    Comments (74) | Send Message
    CUR jumped on this news, to no one's surprise.
    14 Mar 2014, 02:12 PM Reply Like
  • jgoldston0
    , contributor
    Comments (9) | Send Message
    That's the spark this stock needed for the next leg up!
    14 Mar 2014, 02:18 PM Reply Like
  • Homeeoo
    , contributor
    Comment (1) | Send Message
    Organovo here we come...American company...under American regulations...doing good under American legislation....
    14 Mar 2014, 03:03 PM Reply Like
    , contributor
    Comments (9) | Send Message
    I'm just stunned that ACTC isn't mentioned above as being in the Regenerative Medicine "space". They are, unfortunately, in a news black out right now because they are publishing their interim TLD in a peer reviewed journal, which takes Toooooo long.


    However, their SMD and AMD results have been nothing short of stunning, as has leaked out. Their stem cell treatment regenerates the RPE layer of the eye and saves the rods and cones that would otherwise die. In a 'slip', Dr. Lanza, the genius behind ACTC, said one patient had moved from 20/400 to 20/40 and is able to drive again.


    So, whoever is responsible for keeping track had best broaden their net, imho.
    14 Mar 2014, 03:23 PM Reply Like
  • MichaelJ8
    , contributor
    Comments (883) | Send Message
    shhh... i don't want anyone to know about ACTC until its too late... let me accumulate more at a cheap price for as long as I can....
    14 Mar 2014, 05:08 PM Reply Like
  • glider549
    , contributor
    Comments (97) | Send Message
    Then why the phony comment?
    16 Mar 2014, 02:58 AM Reply Like
  • Tile
    , contributor
    Comments (119) | Send Message
    If $BCLI is not included, the list is not complete.
    14 Mar 2014, 03:27 PM Reply Like
  • brewbob47
    , contributor
    Comments (29) | Send Message
    Why isn't Neostem (NBS) included? Knowing our greedy Representatives, it was probably "pay to play". Just kidding, although it wouldn't surprise me.
    14 Mar 2014, 03:29 PM Reply Like
  • gatlingg
    , contributor
    Comments (380) | Send Message
    seeking alpha probably provided the list but whoever did it the list is incomplete. Of course we don't know the definition contained in the senate legislation which could limit participation.
    14 Mar 2014, 03:36 PM Reply Like
  • matty0454
    , contributor
    Comments (28) | Send Message
    About time something like this has happened.long overdue legislation.
    14 Mar 2014, 04:28 PM Reply Like
  • Curtisayee
    , contributor
    Comments (102) | Send Message
    BCLI is not an American company, but they have certainly gotten a lot of support from the Israeli government.
    14 Mar 2014, 04:54 PM Reply Like
  • KWorono
    , contributor
    Comments (8) | Send Message
    Great that public opinion of regenerative medicine is high, but we'll have to see if this bill passes. Funding for research is already pretty tight. How are they gonna scrap together a budget for this thing?
    14 Mar 2014, 05:25 PM Reply Like
  • MedTechBio
    , contributor
    Comments (3264) | Send Message
    Budget deficit has declined over 200B year over year. There's some room.
    14 Mar 2014, 06:37 PM Reply Like
  • wafflemaker
    , contributor
    Comments (74) | Send Message
    None of this matters when it comes to some of the big players. They're already spending the money and clinical trials are having success. We're about 5 years behind the Japanese on this one. The news sent share prices skyrocketing -- CUR, specifically -- because it confirmed what people were feeling. This isn't the future of medicine, it's quickly becoming the present. I was scared, but CUR could be 100-300 dollars a share in a couple of years. And closer to the latter number to boot.
    14 Mar 2014, 11:58 PM Reply Like
  • luciusrwebb
    , contributor
    Comment (1) | Send Message
    SVFC should also be included on this list
    15 Mar 2014, 12:25 AM Reply Like
  • RBerutti
    , contributor
    Comment (1) | Send Message
    Why scrap together a budget? They will just steal it from our kids and grandkids like they do with everything else. In the meantime, at least our stocks will see some benefit.
    15 Mar 2014, 02:13 AM Reply Like
  • ECapo
    , contributor
    Comments (737) | Send Message
    " establish a national strategy to support regenerative medicine (RM) research."
    can anybody tell me what this really does that is going to help unless it gives more money to support research?
    15 Mar 2014, 12:53 PM Reply Like
  • seswoles
    , contributor
    Comments (30) | Send Message
    ATHX is the company with the best chance of becoming the next biotech Titan
    15 Mar 2014, 11:49 PM Reply Like
  • captdot
    , contributor
    Comments (5) | Send Message
    I guess I'm not as positive about the government getting involved. Burdensome regulations, which is the wont of most bureaucrats, can stifle many good intentions and innovation.


    Anyone know the number of the bill? I can't find the text. It's always interesting to read the full text to see what is really in it. Also, it will be interesting to see any differences between this bill and those previously introduced in 2010 & 2011.


    I found that a council (bureaucracy) will be established by DHHS to develop and maintain a national strategy for the promotion of regenerative medicine research and development. The Council would be tasked with identifying priorities and sources of funding for research into regenerative medicine and recommending policies to overcome barriers in research and product development. We shall see...
    16 Mar 2014, 12:07 PM Reply Like
  • hhess13892
    , contributor
    Comments (745) | Send Message
    Does this mean we all get free printers?
    16 Mar 2014, 09:08 PM Reply Like
  • toosmarttofail
    , contributor
    Comments (699) | Send Message
    Peer-reviewed article says hESCs about 30,000x more potent than adult cells:



    As I've been saying, adult cells are *pure junk* compared to embryonic.
    23 Mar 2014, 11:50 PM Reply Like
  • User 3950401
    , contributor
    Comments (556) | Send Message
    "...and the maintenance of a national strategy for the promotion of RM R&D..."


    The government is going to establish a national strategy for the promotion of RM R&D??? LOL! We can't pass a budget, but we can create a strategy for research into regenerative medicine...


    Haven't all the companies in this area established their own strategies and are doing just fine without any help from government up to this point?
    28 Mar 2014, 10:43 PM Reply Like
  • ECapo
    , contributor
    Comments (737) | Send Message
    very well put!
    29 Mar 2014, 11:43 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs